Envista Holdings Corp

NYSE:NVST

Medical - Equipment & Services

Healthcare
$23.75 +3.06%

+$0.76 today

Market cap
$3.81B
Beta
0.89
P/E (TTM)
62.0
EPS (TTM)
$0.41
52W Low $18.32High $30.42

Volume 1.92M

Average 2.94M

NVST Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Envista Holdings CorpNYSE: NVST

Other Income / Expenses · Q3 FY2026 · quarter ended Oct 2026

Other income / expenses remains negative

Q3 FY2026 other income / expenses was -$15M, compared with -$14.9M a year earlier. Trailing-twelve-month other income / expenses was -$49.4M.

Context

  • Other income / expenses amounted to 1.8% of revenue in FY2025, unchanged from a year earlier.
  • Other income / expenses grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near -$15M or moves back toward the trailing-twelve-month quarterly average of -$12.35M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterOct 2026
-$15M-154.2% QoQ
Last fiscal yearDec 2025
-$48.5M-4.3% YoY
LTMOct 2026
-$49.4M-10.8% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.7%——
1 year-4.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(48.5M) USD
Year-over-year change
-4.3%

Other Income / Expenses vs competitors

How NVST compares with its peers on the latest reported figures

  • NVST's LTM Oct 2026 other income / expenses of -$49.4M is the 8th highest of the 11 companies compared; the peer median is -$13.74M.
  • Its year-over-year change of -10.8% is the 5th highest of 11, against a peer median of -21.7%.
  • Other income / expenses amounts to 1.7% of revenue for NVST, versus a peer median of 4.8%.
NVST Competitors Peer median
Other Income / Expenses for NVST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
APGEApogee Therapeutics, Inc.LTM Jun 2026$34.02M +2.1%——
GRALGRAIL, Inc.LTM Jun 2026$29.78M -13.0%—18.0%
DYNDyne Therapeutics, Inc.LTM Jun 2026$17.55M -37.4%+97.2%—
PRVAPrivia Health Group, Inc.LTM Jun 2026$11.23M +9.3%+161.6%0.5%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026-$11.65M -164.6%—1.4%
ALHCAlignment Healthcare, Inc.LTM Mar 2026-$15.83M +36.6%—0.4%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-$43.77M -30.4%—6.5%
NVSTEnvista Holdings CorpLTM Oct 2026-$49.4M -10.8%—1.7%
CONConcentra Group Holdings Parent, Inc.LTM Sep 2026-$103.76M +5.5%—4.4%
ICUIICU Medical, Inc.LTM Jun 2026-$112.63M -110.5%—5.2%
XRAYDENTSPLY SIRONA Inc.LTM Mar 2026-$788M -1112.3%—21.4%
Peer median (excluding NVST) -$13.74M-21.7%+129.4%4.8%

Competitors are the stored peer set for NVST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.51B2.57B2.57B2.51B2.72B
Cost of Revenue1.05B1.08B1.12B1.12B1.22B
Gross Profit1.46B1.49B1.45B1.39B1.5B
Gross Margin58.3%57.9%56.5%55.4%55.0%
Research & Development100.5M100.1M93.8M99.1M114M
Selling, General & Admin989.5M1.03B1.03B1.14B1.16B
Operating Expenses1.16B1.17B1.42B2.43B1.27B
Depreciation & Amortization151.9M162.1M162.6M123.1M116M
EBITDA524.3M522M490M279.5M329.8M
EBITDA Margin20.9%20.3%19.1%11.1%12.1%
Operating Income306.2M319.2M31.5M(1.04B)225.7M
Operating Margin12.2%12.4%1.2%-41.4%8.3%
Interest Income00000
Interest Expense54.1M38.4M63.4M46.4M36.6M
Other Income / Expenses(51.7M)(35.3M)(86.4M)(46.5M)(48.5M)
Income Before Tax254.5M283.9M(54.9M)(1.08B)177.2M
Pre-Tax Margin10.1%11.1%-2.1%-43.2%6.5%
Income Tax Expense(9M)45.9M45.3M33.9M130.2M
Net Income340.5M243.1M(100.2M)(1.12B)47M
Net Margin13.6%9.5%-3.9%-44.6%1.7%
EPS (Basic)1.631.46(0.60)(6.50)0.28
EPS (Diluted)1.481.34(0.60)(6.50)0.28
Weighted Avg Shares161.2M162.9M166.9M172.2M168M
Weighted Avg Shares (Diluted)177.6M177.6M166.9M172.2M169.2M

Envista Holdings Corp

NYSE:NVST

Intrinsic Alpha fair value

Locked

Current Price

$23.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.